RAYMUNDO GARCIA-DWYER: Open Payments
NPI 1427406032 · MILWAUKEE, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$544 in 25 payments from 10 companies in 2025. Trend: 2023 $163 · 2024 $773 · 2025 $544
Food & beverage: $544
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 5 | $177 |
| ABBVIE INC. | 9 | $161 |
| PFIZER INC. | 4 | $70 |
| AstraZeneca Pharmaceuticals LP | 1 | $26 |
| Astellas Pharma US Inc | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Amgen Inc. | 1 | $17 |
Products named: Epclusa, VRAYLAR, NURTEC ODT, LINZESS, UBRELVY, AIRSUPRA, Veozah, CAMZYOS.
Industry payments across WI — which companies pay providers there.
